191 related articles for article (PubMed ID: 35603955)
1. Clinical outcomes of EGFR-TKIs in advanced squamous cell lung cancer.
Si JF; Xiang J; Wei JW; Hao Y; Song ZB
Neoplasma; 2022 Jul; 69(4):976-982. PubMed ID: 35603955
[TBL] [Abstract][Full Text] [Related]
2. Clinical outcomes of immune checkpoint inhibitors to treat non-small cell lung cancer patients harboring epidermal growth factor receptor mutations.
Si J; Hao Y; Wei J; Xiang J; Xu C; Shen Q; Song Z
BMC Pulm Med; 2023 May; 23(1):158. PubMed ID: 37147602
[TBL] [Abstract][Full Text] [Related]
3. The effect of EGFR-TKIs on survival in advanced non-small-cell lung cancer with EGFR mutations: A real-world study.
Yu X; Si J; Wei J; Wang Y; Sun Y; Jin J; Zhang X; Ma T; Song Z
Cancer Med; 2023 Mar; 12(5):5630-5638. PubMed ID: 36380563
[TBL] [Abstract][Full Text] [Related]
4. [Clinical observation of EGFR-TKI as a first-line therapy on advanced non-small cell lung cancer].
Li J; Qu L; Wei X; Gao H; Wang W; Qin H; Tang C; Guo W; Wang H; Liu X
Zhongguo Fei Ai Za Zhi; 2012 May; 15(5):299-304. PubMed ID: 22613337
[TBL] [Abstract][Full Text] [Related]
5. The efficacy of immune checkpoint inhibitors in advanced
Hu J; Huang D; Wang Y; Li D; Yang X; Fu Y; Du N; Zhao Y; Li X; Ma J; Hu Y
Front Immunol; 2022; 13():975246. PubMed ID: 36159795
[TBL] [Abstract][Full Text] [Related]
6. Effectiveness of high-dose third-generation EGFR-tyrosine kinase inhibitors in treating EGFR-mutated non-small cell lung cancer patients with leptomeningeal metastasis.
Wu H; Zhang Q; Zhai W; Chen Y; Yang Y; Xie M; Huang Z; Xu Y; Li H; Gong L; Yu S; Fan Y; Chen K
Lung Cancer; 2024 Feb; 188():107475. PubMed ID: 38266613
[TBL] [Abstract][Full Text] [Related]
7. First-line treatment with irreversible tyrosine kinase inhibitors associated with longer OS in EGFR mutation-positive non-small cell lung cancer.
Su PL; Chen CW; Wu YL; Lin CC; Su WC
Thorac Cancer; 2021 Feb; 12(3):287-296. PubMed ID: 33336895
[TBL] [Abstract][Full Text] [Related]
8. Efficacy of first-line treatment with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) alone or in combination with chemotherapy for advanced non-small cell lung cancer (NSCLC) with low-abundance mutation.
Yan X; Wang H; Li P; Zhang G; Zhang M; Yang J; Zhang X; Zheng X; Ma Z
Lung Cancer; 2019 Feb; 128():6-12. PubMed ID: 30642455
[TBL] [Abstract][Full Text] [Related]
9. Clinical outcomes of EGFR-TKI treatment and genetic heterogeneity in lung adenocarcinoma patients with EGFR mutations on exons 19 and 21.
Yu JY; Yu SF; Wang SH; Bai H; Zhao J; An TT; Duan JC; Wang J
Chin J Cancer; 2016 Mar; 35():30. PubMed ID: 27001083
[TBL] [Abstract][Full Text] [Related]
10. Comprehensive characterization and clinical impact of concomitant genomic alterations in EGFR-mutant NSCLCs treated with EGFR kinase inhibitors.
Cheng Y; Ma L; Liu Y; Zhu J; Xin Y; Liu X; Wang Y; Zhang T; Yang C; Wang S; Cui H; Zhang L; Dai J; Shao L; Lin J; Ye J; Liu H
Lung Cancer; 2020 Jul; 145():63-70. PubMed ID: 32408134
[TBL] [Abstract][Full Text] [Related]
11. Efficacy of icotinib in advanced lung squamous cell carcinoma.
Liang S; Xu Y; Tan F; Ding L; Ma Y; Wang M
Cancer Med; 2018 Sep; 7(9):4456-4466. PubMed ID: 30109777
[TBL] [Abstract][Full Text] [Related]
12. The association between clinical prognostic factors and epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) efficacy in advanced non-small-cell lung cancer patients: a retrospective assessment of 94 cases with EGFR mutations.
Lin JH; Lin D; Xu L; Wang Q; Hu HH; Xu HP; He ZY
Oncotarget; 2017 Jan; 8(2):3412-3421. PubMed ID: 27926500
[TBL] [Abstract][Full Text] [Related]
13. Next-generation sequencing of tissue and circulating tumor DNA: Resistance mechanisms to EGFR targeted therapy in a cohort of patients with advanced non-small cell lung cancer.
Zhang Y; Xiong L; Xie F; Zheng X; Li Y; Zhu L; Sun J
Cancer Med; 2021 Jul; 10(14):4697-4709. PubMed ID: 34173341
[TBL] [Abstract][Full Text] [Related]
14. Impact of coexisting gene mutations in EGFR-mutated non-small cell lung cancer before treatment on EGFR T790M mutation status after EGFR-TKIs.
Takeda M; Sakai K; Hayashi H; Tanaka K; Haratani K; Takahama T; Kato R; Yonesaka K; Nishio K; Nakagawa K
Lung Cancer; 2020 Jan; 139():28-34. PubMed ID: 31710890
[TBL] [Abstract][Full Text] [Related]
15. Comparison of epidermal growth factor receptor tyrosine kinase inhibitors for patients with lung adenocarcinoma harboring different epidermal growth factor receptor mutation types.
Park S; Lee SY; Kim D; Sim YS; Ryu JS; Choi J; Lee SH; Ryu YJ; Lee JH; Chang JH
BMC Cancer; 2021 Jan; 21(1):52. PubMed ID: 33430803
[TBL] [Abstract][Full Text] [Related]
16. Clinical outcomes of lung adenocarcinoma patients harboring uncommon epidermal growth factor receptor (EGFR) mutations treated with EGFR-tyrosine kinase inhibitors (TKIs).
Si J; Gu X; Wang W; Ying S; Song Z
Ann Palliat Med; 2022 May; 11(5):1624-1634. PubMed ID: 35016520
[TBL] [Abstract][Full Text] [Related]
17. Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Squamous Cell Lung Cancer.
Xu J; Chu T; Jin B; Dong X; Lou Y; Zhang X; Wang H; Zhong H; Shi C; Gu A; Xiong L; Zhao Y; Jiang L; Zhang J; Han B
Clin Lung Cancer; 2016 Jul; 17(4):309-14. PubMed ID: 26725853
[TBL] [Abstract][Full Text] [Related]
18. Impact of angiogenesis inhibitor eligibility on the prognosis of patients with non-small cell lung cancer harboring EGFR mutation.
Kodama H; Kenmotsu H; Kawabata T; Notsu A; Yabe M; Nishioka N; Miyawaki E; Miyawaki T; Mamesaya N; Kobayashi H; Omori S; Wakuda K; Ono A; Naito T; Murakami H; Takahashi T
Cancer Med; 2021 Nov; 10(21):7503-7513. PubMed ID: 34587359
[TBL] [Abstract][Full Text] [Related]
19. Specific Gene Co-variation Acts Better Than Number of Concomitant Altered Genes in Predicting EGFR-TKI Efficacy in Non-small-cell Lung Cancer.
Zhu YJ; Qu X; Zhan DD; Chen HH; Li HP; Liu LR; Chen X; Liu YH; Li Y; Bai JP; Ye S; Zhang HB
Clin Lung Cancer; 2021 Jan; 22(1):e98-e111. PubMed ID: 33067127
[TBL] [Abstract][Full Text] [Related]
20. Effect of EGFR amplification on the prognosis of EGFR-mutated advanced non-small-cell lung cancer patients: a prospective observational study.
Peng D; Liang P; Zhong C; Xu P; He Y; Luo Y; Wang X; Liu A; Zeng Z
BMC Cancer; 2022 Dec; 22(1):1323. PubMed ID: 36528578
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
